Sotagliflozin attenuates atrial oxidative stress and the susceptibility to atrial fibrillation by activating the NRF2/HO-1 pathway
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115461 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Fanqi Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha 410000, China. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Atrial Fibrillation, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Department of Science and Technology of Hunan Province.
Abstract (Originalsprache)
BACKGROUND: Atrial fibrillation (AF) is the most common form of sustained cardiac arrhythmia. Sotagliflozin (Sota), an SGLT1/2 inhibitor, has demonstrated potential cardiovascular protective effects, but its role and underlying mechanisms in AF remain unclear. This study aims to investigate the effects of Sota on AF and explore the underlying mechanisms. METHODS: Establishing an AF model by injecting acetylcholine/calcium chloride (Ach/CaCl2) through the tail vein of mice. Mice were randomly assigned to four groups: Control, Sota, AF model, and AF model + Sota. Atrial structural changes, electrophysiological remodeling, oxidative stress levels, and inflammatory biomarkers were evaluated. Additionally, potential signaling pathways affected by Sota were examined, with relevant signaling molecules analyzed. RESULTS: Sota treatment significantly reduced AF susceptibility in the Ach/CaCl2-induced AF model, improving atrial remodeling. Sota notably diminished the oxidative stress induced by AF in the atria, reduced pro-inflammatory factors, and restored mitochondrial morphology and function. Confocal microscopy and Western blot (WB) analyses confirmed that Sota promoted the nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2) and activated the NRF2/HO-1 pathway. Furthermore, the NRF2 inhibitor ML385 significantly reversed Sota's antioxidant effects and abolished its protective effects on atrial. CONCLUSIONS: Sota alleviates atrial oxidative stress, improves atrial remodeling, and significantly reduces susceptibility to AF by activating the NRF2/HO-1 pathway. These findings offer new insights into the potential therapeutic application of Sota in the treatment of AF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha 410000, China.
- Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha 410000, China. Electronic address: qiuzhenlin@csu.edu.cn.
- Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha 410000, China. Electronic address: qimingliu@csu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Department of Science and Technology of Hunan Province
Zitieren
APA
Li, F., Xie, M., Zeng, G., Zhu, J., Zhou, J., Tan, S., Lin, Q., & Liu, Q. (2025). Sotagliflozin attenuates atrial oxidative stress and the susceptibility to atrial fibrillation by activating the NRF2/HO-1 pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115461
Vancouver
Li F, Xie M, Zeng G, Zhu J, Zhou J, Tan S, et al. Sotagliflozin attenuates atrial oxidative stress and the susceptibility to atrial fibrillation by activating the NRF2/HO-1 pathway. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115461
BibTeX
@article{Li2025,
author = {Li, Fanqi and Xie, Murong and Zeng, Gaoming and Zhu, Jiayi and Zhou, Jiabao and Tan, Siyuan and Lin, Qiuzhen and Liu, Qiming},
title = {Sotagliflozin attenuates atrial oxidative stress and the susceptibility to atrial fibrillation by activating the NRF2/HO-1 pathway},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115461}
}
EUVIMED